Modern Diagnostic IPO GMP is creating buzz in the market this week. Investors are keenly tracking the Grey Market Premium, which currently stands around ₹68, showing strong demand from early traders. The IPO opens on 28th December 2025 and closes on 2nd January 2026. The live IPO GMP today reflects high investor sentiment, and many retail players are gearing up to apply before the window closes.
Table of Contents
Modern Diagnostic IPO GMP Live Movement Day Wise
| Date | IPO GMP | IPO Price | Estimated Listing Gain |
|---|---|---|---|
| 06 Jan 2026 | ₹13 | ₹90 | ₹103 (14%) |
| 03 Jan 2026 | ₹16 ▲ | ₹90 | ₹106 (17%) |
| 26 Dec 2025 | ₹12 ▲ | ₹90 | ₹102 (13%) |
| 26 Dec 2025 | ₹0 | ₹90 | ₹0 (0%) |
| 25 Dec 2025 | ₹0 | ₹90 | ₹0 (0%) |
| 24 Dec 2025 | ₹0 | ₹90 | ₹0 (0%) |
Modern Diagnostic IPO Dates Timeline
| Event | Date |
|---|---|
| IPO Open Date | December 31, 2025 |
| IPO Close Date | January 2, 2026 |
| Basis of Allotment | January 5, 2026 |
| Refunds Initiation | January 6, 2026 |
| Credit to Demat | January 6, 2026 |
| IPO Listing Date | January 7, 2026 |
| UPI Mandate Cut-off | January 2, 2026 – 5 PM |
Modern Diagnostic IPO Overview
| Parameter | Details |
|---|---|
| Total Issue Size | Approx ₹37 Crores (fresh issue of 40,99,200 shares) |
| IPO Price Band | ₹85 to ₹90 Per Share |
| Minimum Investment (Retail) | ₹2,88,000 (3,200 shares at upper band) |
| Lot Size | 3,200 Shares (1 retail lot) |
| Issue Type | Book Build Issue, SME IPO |
| IPO Listing | BSE SME |
| DHRP Draft Link | View |
Business Model Explained
Modern Diagnostic is a fast-growing healthcare and pathology brand that operates a chain of diagnostic centers across India. The company focuses on providing affordable, high-quality testing services in both metro and tier-2 cities. Its core services include pathology tests, radiology imaging, preventive screening packages, and digital health reports through its online platform.
The company has built a reliable network where technology meets trust. With an increasing number of health-conscious individuals post-pandemic, Modern Diagnostic has carved its niche by blending advanced medical equipments, quick turnaround times, and patient-first service. It earns its revenue primarily through direct testing services, B2B hospital partnerships, and pre-employment health screening programs for corporates.
As the healthcare sector in India continues to expand, diagnostics is emerging as one of the fastest-growing segments. The company’s data-driven expansion plans, combined with its focus on affordable wellness diagnostics, have placed it at the center of investor discussions. That’s why Modern Diagnostic IPO GMP discussions across investor circles are heating up, reflecting optimistic growth potential.
Strengths
Modern Diagnostic stands out for its strong brand recall, trusted accuracy, and consistent service quality. Its rapid expansion into new cities, affordable test pricing, and partnerships with hospitals make the IPO attractive. The rising Modern Diagnostic IPO GMP also indicates solid institutional and retail confidence.
Weaknesses / Risks
Despite its growth story, the company faces key challenges like rising raw material costs, competitive pricing from regional players, and dependency on external suppliers for medical equipment. Investors should also consider healthcare policy changes and margin pressures. Some investors are tracking the Modern Diagnostic IPO GMP carefully before taking final decisions.
Popular Products from Modern Diagnostic
Modern Diagnostic offers comprehensive test packages for end users, including blood tests, allergy panels, full-body health checkups, and radiology scans. They also provide home sample collection services, making it easy for customers to access healthcare without visiting centers. Their preventive health plans are popular among young professionals and families.
